Somewhat Positive News Coverage Somewhat Unlikely to Affect Coherus BioSciences (CHRS) Share Price
Media stories about Coherus BioSciences (NASDAQ:CHRS) have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern ranks the sentiment of press coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Coherus BioSciences earned a news sentiment score of 0.19 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0453486253148 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next several days.
Here are some of the news stories that may have effected Accern Sentiment’s analysis:
- Coherus Biosciences : Today’s Research Report Coverage on Biotech Stocks — Bellicum Pharma, Cara Therapeutics, Cerus, and Coherus Biosciences (4-traders.com)
- Coherus BioSciences, Inc. – Value Analysis (NASDAQ:CHRS) : August 30, 2017 (finance.yahoo.com)
- COHERUS BIOSCIENCES, INC. : Other Events, Financial Statements and Exhibits (form 8-K) (4-traders.com)
- Buy or Hold? A Look at What the Technicals Are Saying About Coherus BioSciences Inc (CHRS) – Evergreen Caller (evergreencaller.com)
Several analysts have issued reports on CHRS shares. Cowen and Company restated an “outperform” rating and issued a $45.00 target price on shares of Coherus BioSciences in a research note on Tuesday, June 13th. Citigroup Inc. lowered their target price on Coherus BioSciences from $38.00 to $33.00 and set a “buy” rating on the stock in a research note on Tuesday, June 13th. Robert W. Baird lowered their target price on Coherus BioSciences from $40.00 to $37.00 and set an “outperform” rating on the stock in a research note on Tuesday, June 13th. BMO Capital Markets started coverage on Coherus BioSciences in a research note on Friday, May 5th. They issued an “outperform” rating and a $54.00 target price on the stock. Finally, Maxim Group lowered their target price on Coherus BioSciences from $44.00 to $40.00 and set a “buy” rating on the stock in a research note on Monday, June 12th. Two equities research analysts have rated the stock with a sell rating and ten have assigned a buy rating to the company’s stock. Coherus BioSciences has an average rating of “Buy” and an average target price of $34.70.
Shares of Coherus BioSciences (NASDAQ CHRS) opened at 14.25 on Thursday. Coherus BioSciences has a 52 week low of $10.80 and a 52 week high of $31.98. The company’s market capitalization is $731.68 million. The firm has a 50 day moving average price of $13.05 and a 200 day moving average price of $18.55.
Coherus BioSciences (NASDAQ:CHRS) last posted its quarterly earnings results on Monday, August 7th. The biotechnology company reported ($1.08) EPS for the quarter, beating the consensus estimate of ($1.29) by $0.21. Coherus BioSciences had a negative net margin of 73.89% and a negative return on equity of 307.41%. The company had revenue of $1.40 million for the quarter. Equities analysts forecast that Coherus BioSciences will post ($5.13) EPS for the current year.
In other Coherus BioSciences news, insider Alan C. Herman sold 17,535 shares of the company’s stock in a transaction on Tuesday, August 8th. The shares were sold at an average price of $15.02, for a total value of $263,375.70. Following the sale, the insider now directly owns 49,651 shares of the company’s stock, valued at $745,758.02. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 26.28% of the stock is currently owned by corporate insiders.
COPYRIGHT VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Affect Coherus BioSciences (CHRS) Share Price” was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this story on another site, it was copied illegally and reposted in violation of U.S. and international trademark & copyright laws. The legal version of this story can be read at https://theolympiareport.com/2017/08/31/somewhat-positive-news-coverage-somewhat-unlikely-to-affect-coherus-biosciences-chrs-share-price.html.
Coherus BioSciences Company Profile
Coherus BioSciences, Inc is a late-stage clinical biologics platform company. The Company is engaged in the business of developing and commercializing biosimilar products. The Company’s business is organized around therapeutic franchises, including Oncology biosimilar candidates pegfilgrastim (Neulasta) and bevacizumab (Avastin); Immunology (Anti-TNF) biosimilar candidates etanercept (Enbrel) and adalimumab (Humira); Ophthalmology biosimilar candidate ranibizumab (Lucentis), and Multiple sclerosis small molecule therapeutic candidate, CHS-131.
Receive News & Ratings for Coherus BioSciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coherus BioSciences Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.